Exelixis | EXEL - Umsatzerlöse

Aktienkurs
45.51
Täglich Wechseln
0.57 1.26%
Monatlich
8.47%
Jährlich
18.38%
Q2 Prognose
43.98




Der Umsatz Veränderung Datum
Acadia Pharmaceuticals USD 284M 5.4M 2025-12
Agios Pharmaceuticals USD 19.97M 7.07M 2025-12
Akebia Therapeutics USD 57.62M 1.14M 2025-12
Amgen USD 9.9B 340M 2025-12
AstraZeneca USD 15.5B 313M 2025-12
Bayer EUR 11.44B 1.78B 2025-12
BioMarin Pharmaceutical USD 875M 99M 2025-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Cytokinetics USD 17.76M 15.83M 2025-12
Eisai JPY 219.94B 22.58B 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Esperion Therapeutics USD 168.45M 81.14M 2025-12
Exelixis USD 598.66M 860K 2025-12
Genmab DKK 1.06B 36M 2025-12
Glaxosmithkline GBP 11.46B 59.16M 2025-12
Incyte USD 1.51B 140M 2025-12
Ionis Pharmaceuticals USD 203M 46M 2025-12
MacroGenics USD 41.23M 31.61M 2025-12
Merck USD 16.4B 880M 2025-12
Moderna USD 678M 342M 2025-12
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
Novartis USD 13.86B 50M 2025-12
Pfizer USD 17.58B 880M 2025-12
Puma Biotechnology USD 80.54M 33.46M 2024-09
Sanofi EUR 12.14B 65M 2026-03
Takeda JPY 1.19T 80B 2025-12
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
Xencor USD 28.24M 7.24M 2025-12